Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Lifecore To Contact Him Directly To Discuss Their Options If you suffered losses exceeding $75,000 in Lifecore between October 7, 2020 and March 19, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Aug. 22, 2024 (GLOBE N ...

SAN DIEGO, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

Core Viewpoint - Lifecore Biomedical, Inc. is facing a class action lawsuit due to alleged false and misleading statements regarding its financial reporting and internal controls during the class period from October 7, 2020, to March 19, 2024 [1][5]. Group 1: Class Action Details - The Rosen Law Firm is reminding investors who purchased Lifecore securities during the class period of the September 27, 2024, deadline to become a lead plaintiff in the class action [1][3]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the Rosen Law Firm [3][6]. Group 2: Allegations Against Lifecore - The lawsuit claims that Lifecore had deficient internal controls over financial reporting, leading to inaccurate financial statements that required restatement [5]. - It is alleged that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing its ability to file periodic reports with the SEC in compliance with NASDAQ requirements [5]. - The lawsuit asserts that Lifecore's financial position and prospects were materially overstated, resulting in misleading public statements [5]. Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, enhancing the firm's credibility in handling such cases [4].

NEW YORK, Aug. 14, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arra ...

SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Lifecore Biomedical, Inc. (NASDAQ: LFCR) securities between October 7, 2020 and March 19, 2024. Lifecore operates as an integrated contract development and manufacturing organization in the U.S. and internationally. The Company purportedly designs, develops, manufactures, and sells differentiated products for biomaterial ...

NEW YORK, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Lifecore Biomedical, Inc. ("Lifecore" or "the Company") (NASDAQ: LFCR) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Lif ...

Group 1 - A class action has been filed against Lifecore Biomedical, Inc. (LFCR) for alleged misleading statements regarding its business and financial reporting during the Class Period from October 7, 2020, to March 19, 2024 [1][2] - The Complaint claims that LFCR had deficient internal controls over financial reporting, leading to inaccurate financial statements that required restatement [2] - The company's stock reportedly lost at least half its value during the Class Period due to adverse disclosures made by the Defendants [3] Group 2 - Investors who acquired LFCR securities are encouraged to contact the firm before the lead plaintiff motion deadline of September 27, 2024 [4] - The firm has extensive experience in representing public pension funds and high net-worth investors in securities class actions [5] - The firm partner has been recognized among America's Top 100 High Stakes Litigators, indicating a strong reputation in handling complex litigation cases [6]

Core Viewpoint - A class action lawsuit has been filed against Lifecore Biomedical, Inc. for alleged deficiencies in financial reporting and internal controls, impacting the company's share price and financial statements [1][2][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired Lifecore securities from October 7, 2020, to March 19, 2024, with a deadline of September 27, 2024, for lead plaintiff applications [1]. - Allegations include Lifecore maintaining deficient internal controls, resulting in inaccurate financial statements that require restatement [3]. - The company’s remediation efforts regarding these deficiencies were deemed ineffective, impairing its ability to file timely reports with the SEC [3]. Group 2: Financial Impact - Between September 2022 and February 2024, Lifecore's share price declined due to disclosures about material weaknesses in internal controls and delays in SEC filings [2]. - The lawsuit claims that Lifecore's financial position and prospects were materially overstated as a result of these issues [3].

NEW YORK, Aug. 8, 2024 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangeme ...

Core Viewpoint - Lifecore Biomedical, Inc. is under investigation for potential securities law violations, with a federal class action lawsuit filed against the company, highlighting significant internal control deficiencies and misleading financial statements [2][4]. Company Overview - Lifecore Biomedical, Inc. trades on NASDAQ under the ticker LFCR and has faced scrutiny regarding its financial reporting practices [2]. Legal Proceedings - A federal securities class action has been initiated against Lifecore, with a deadline of September 27, 2024, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Lifecore and its executives made false statements and failed to disclose critical information regarding the company's financial health and internal controls [4]. Financial Reporting Issues - Lifecore disclosed on January 10, 2024, that it could not file its Quarterly Report for the period ended November 26, 2023, due to ongoing restatement processes, leading to a stock price drop of 3.98% [5]. - Following a notification from NASDAQ regarding non-compliance with listing requirements due to delayed filings, Lifecore's stock fell by 1.6% on January 16, 2024 [6][7]. - On February 16, 2024, Lifecore received a Staff Delisting Determination from NASDAQ, which could lead to the delisting of its securities [8]. - The company filed its Annual Report on Form 10-K on March 20, 2024, revealing that prior financial statements needed restatement due to identified errors [9]. Stock Performance - Lifecore's stock price experienced significant declines, including a 30.32% drop to close at $5.01 per share on March 20, 2024, following the announcement of the need for restatements [9].